Navigation Links
VIA Pharmaceuticals Complies With NASDAQ Rules
Date:3/27/2009

SAN FRANCISCO, March 27 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced, in compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), that the independent audit report included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and filed with the Securities and Exchange Commission on March 27, 2009 contained explanatory paragraphs relating to the Company's ability to continue as a going concern. The disclosure in this press release is required under the above NASDAQ rule and does not represent any change to the Company's Annual Report on Form 10-K filed on March 27, 2009 with the Securities and Exchange Commission.

The Company also announced today that, as expected, it received a deficiency letter dated March 24, 2009 from NASDAQ Staff notifying the Company that as a result of the death over the March 21st weekend of Richard L. Anderson, an independent director and member of the Company's Audit Committee, Compensation Committee and Nominating and Governance Committee, the Company's Board of Directors is no longer comprised of a majority of independent directors and the Company's Audit Committee is no longer comprised of at least three independent directors, as required for continued listing by NASDAQ Marketplace Rules 4350(c)(1) and 4350(d)(2)(A), respectively. In accordance with NASDAQ Marketplace Rules, the Company has until September 17, 2009 to regain compliance with the NASDAQ listing standards. The Board of Directors of the Company intends to identify candidates to replace Mr. Anderson and appoint a new director who satisfies the independence requirements of the NASDAQ Marketplace Rules prior to September 17, 2009.

About VIA
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
3. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
4. Isis Pharmaceuticals to Present at the 4th Annual Citi Biotech Day
5. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
6. Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*
7. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
8. Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer
9. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
10. Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009
11. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , Dec. 15, 2014 Organovo Holdings, ... company focused on delivering breakthrough 3D bioprinting technology,  ... and collaborators of its exVive3D TM Human ... available in full commercial release on November 18, ... resulting in several awards for innovation. ...
(Date:12/13/2014)... , Dec. 12, 2014 /CNW/ - MaRS and Virgin Unite ... that they have joined forces to support Canadian entrepreneurs tackling ... Virgin Group Founder was at the MaRS Centre to announce ... national impact venture fund. This fund has $1 million in ... Vancouver -based Mindset Social Innovation Foundation, founded by ...
(Date:12/13/2014)... (PRWEB) December 13, 2014 According to ... million people between now and 2030." If a population ... the seventh most populous state in the country. , ... gathering at the Future of North Carolina Forum on ... Do we have the necessary infrastructure in place? Enough ...
(Date:12/13/2014)... SAN ANTONIO , Dec. 12, 2014 /PRNewswire/ ... presentation of data at the San Antonio Breast Cancer ... epoetin alfa plus best supportive care (BSC) versus BSC ... breast cancer receiving standard chemotherapy. This non-inferiority trial did ... out a 15 percent or greater increase in the ...
Breaking Biology Technology:Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3North Carolina Chamber of Commerce: Asking Questions & Gathering Answers with a Futurist 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12
... YOKOHAMA, Japan, Aug. 27 MaxCyte,Inc. and ... the signing of an,exclusive license, development and ... system to support clinical studies and,commercialization of ... of the agreement, MaxCyte will provide the ...
... RESEARCH TRIANGLE PARK, N.C., Aug. 27 ... Pharmaceuticals, Inc., a,clinical-stage biopharmaceutical company specializing in ... private placement of C$26 million,(US$25 million) in ... investment by NovaQuest, the strategic partnering group,of ...
... Aug. 27 /Xinhua-PRNewswire-FirstCall/ -- China Technology,Development Group Corporation ... appointment of Charlene Hua as the Company,s new ... a board,resolution passed on the same date. This ... the Company. As Chief Financial Officer, Ms. ...
Cached Biology Technology:Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan 2Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan 3NovaQuest Advances 'Virtual Development' Model With Strategic Investment in TOPIGEN Pharmaceuticals 2China Technology Announces New Chief Financial Officer 2China Technology Announces New Chief Financial Officer 3
(Date:12/17/2014)...  HITLAB SM announced today its completion ... confirm its adherence to current U.S. Food and ... to conduct regulated smart device and smart phone ... safety and research quality. "HITLAB is ... delivery with innovative technology," said Laura Pugliese ...
(Date:12/17/2014)... Dec. 16, 2014  Automation is fundamentally transforming ... evident than at international borders. Over the past ... have allowed veteran travelers to self process through ... (APC) Kiosks at an increasing number of airports, ... According to Maxine Most , ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... Science Brief presents a roadmap for marine biodiversity science ... provides 95% of the habitable space on Earth and ... health of the oceans and their productive ecosystems which ... life is under significant threat from climate change and ...
... causing alarm among global public health authorities after it killed ... is now linked to two other cases of disease is ... found in bats, according to a genetic analysis to be ... the American Society for Microbiology, on November 20. Researchers studied ...
... including Carnegie Museum of Natural History scientist John ... Necrolestes patagonensis , whose name translates into grave ... This much-debated fossil mammal from South America has ... years. Scientific perseverance, a recent fossil discovery, and ...
Cached Biology News:Europe must not lose momentum in marine biodiversity research 2New coronavirus related to viruses from bats 2New coronavirus related to viruses from bats 3After 121 years, identification of 'grave robber' fossil solves a paleontological enigma 2After 121 years, identification of 'grave robber' fossil solves a paleontological enigma 3After 121 years, identification of 'grave robber' fossil solves a paleontological enigma 4After 121 years, identification of 'grave robber' fossil solves a paleontological enigma 5